hydrazone of 2-nitroacetophenone | 116271-34-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: hydrazone of 2-nitroacetophenone
• 英文别名: 2-Nitroacetophenone hydrazone；[1-(2-Nitrophenyl)ethylidene]hydrazine；1-(2-nitrophenyl)ethylidenehydrazine
• CAS: 116271-34-2
• 化学式: C₈H₉N₃O₂
• 分子量: 179.178
• InChiKey: QJWDISQVXGQOQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  339.3±44.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  hydrazone of 2-nitroacetophenone 在 manganese(IV) oxide 作用下， 以 氯仿 、 水 为溶剂， 反应 0.08h， 生成 1-(2-亚硝基苯基)-乙酮
  参考文献：
  名称：

  Photolabile 1-(2-nitrophenyl)ethyl phosphate esters of adenine nucleotide analogs. Synthesis and mechanism of photolysis

  摘要：

  DOI：

  10.1021/ja00229a036
• 作为产物：
  描述：

  邻硝基苯乙酮 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 hydrazone of 2-nitroacetophenone
  参考文献：
  名称：

  Novel caged luciferin derivatives can prolong bioluminescence imaging in vitro and in vivo

  摘要：

  一组高效的囚禁型荧光素衍生物表现出低细胞毒性，并且在体外和体内表现出延长的生物发光。

  DOI：

  10.1039/c8ra02312c

文献信息

• Adenosine Analogs and Their Use
  申请人：Ben-Zeev Efrat

  公开号：US20110237529A1

  公开（公告）日：2011-09-29

  The invention provides adenosine analog compounds that act at P2Y receptors, e.g., the P2Y 2 receptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.

  该发明提供了在P2Y受体上起作用的腺苷类似化合物，例如P2Y2受体，包括药物组合物；以及将其用于治疗或预防与该受体相关的疾病，例如与粘液分泌有关的疾病，如囊性纤维化、慢性阻塞性肺病（COPD）、哮喘、便秘、慢性特发性便秘、口干（口腔干燥症）、牙龈疾病，以及由放射治疗和化疗引起的癌症的胃肠道问题。
• 一种苯并噻唑衍生物及其合成方法与作为抗 菌药物的应用
  申请人：扬州工业职业技术学院

  公开号：CN110734412B

  公开（公告）日：2021-08-13

  本发明涉及一种苯并噻唑衍生物及其合成方法与作为抗菌药物的应用，所述苯并噻唑衍生物具有式I所示结构：其中R选自H、C1‑C3烷基、C1‑C3烷氧基或卤素。
• Photoregulation of Cytochrome P450 Activity by Using Caged Compound
  作者：Kenichi Morigaki、Kazuyuki Mizutani、Emi Kanemura、Yoshiro Tatsu、Noboru Yumoto、Hiromasa Imaishi

  DOI：10.1021/ac202189h

  日期：2012.1.3

  Cytochrome P450 (P450) species play an important role in the metabolism of xenobiotics, and assaying the activities of P450 is important for evaluating the toxicity of chemicals in drugs and food. However, the lag time caused by the introduction and mixing of sample solutions can become sources of error as the throughput is heightened by increasing the sample number and decreasing the sample volume. To amend this technological obstacle, we developed a methodology to photoregulate the activity of P450 by using photoprotected (caged) compounds. We synthesized caged molecules of nicotinamide adenine dinucleotide phosphate (NADP+) and glucose 6-phosphate (G6P), which are involved in the generation of NADPH (cofactor of P450). The use of caged-G6P completely blocked the P450 catalysis before the UV illumination, whereas caged-NADP+ resulted in a little background reaction. Upon UV illumination, more than 90% of the enzymatic activity could be restored. The use of caged-G6P enabled assays in isolated microchambers (width, 50 μm; height, 50 μm) by encapsulating necessary ingredients in advance and initiating the reaction by UV illumination. The initiation of enzymatic reaction could be observed in a single microchamber. Minimizing uncertainties caused by the introduction and mixing of solutions led to significantly reduced errors of obtained kinetic constants.

  细胞色素 P450（P450）物种在异种生物的代谢过程中发挥着重要作用，而检测 P450 的活性对于评估药物和食品中化学物质的毒性非常重要。然而，随着样品数量的增加和样品量的减少，样品溶液的引入和混合所造成的滞后时间会成为误差的来源。为了克服这一技术障碍，我们开发了一种使用光保护（笼状）化合物对 P450 的活性进行光调节的方法。我们合成了烟酰胺腺嘌呤二核苷酸磷酸（NADP+）和 6-磷酸葡萄糖（G6P）的笼状分子，它们参与生成 NADPH（P450 的辅助因子）。在紫外线照射前，使用笼装 G6P 可完全阻断 P450 的催化反应，而笼装 NADP+ 则会导致少量的背景反应。紫外线照射后，90% 以上的酶活性得以恢复。使用笼式-G6P 可以在隔离的微室（宽 50 μm；高 50 μm）中进行测定，方法是提前封装必要的成分，并通过紫外线照射启动反应。在一个微室中就能观察到酶反应的起始过程。尽量减少溶液的引入和混合所造成的不确定性，大大降低了所得动力学常数的误差。
• 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
  申请人：Pfizer, Inc.

  公开号：US20030013875A1

  公开（公告）日：2003-01-16

  Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances. 1

  公式（I）的化合物、其盐和前药被揭示为鸦片类结合剂，可用于治疗鸦片类介导的疾病，其中取代基的定义如本文所述。还描述了制造这些物质的过程。
• 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
  申请人：Pfizer INC

  公开号：US06313312B1

  公开（公告）日：2001-11-06

  Compounds of formula (I), their salts and prodrugs thereof, where the substituents are as defined herein are disclosed as opiate binding agents useful in the treatment of opiate-mediated conditions. Also described are processes for making such substances.

  本文披露了化学式(I)的化合物、它们的盐和前药，其中置换基的定义如本文所述，这些化合物作为鸦片类药物结合剂在治疗鸦片类介导的疾病方面有用。还描述了制备这些物质的过程。